The Los Angeles Post
U.S. World Business Lifestyle
Today: April 04, 2025
Today: April 04, 2025

Vertex Pharma misses sales estimates on weak demand for older CF treatments

FILE PHOTO: A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston
April 26, 2024
Reuters - Reuters

(Reuters) - Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.

The drugmaker recorded a 35.4% fall in sales of its older CF treatments to $209.2 million.

Cystic fibrosis, affecting around 100,000 people globally, is an inherited disorder that causes severe damage to the lungs, digestive system and other organs.

Vertex said it now expects annual sales of about $9.85 billion from its CF treatments, compared with LSEG estimates of $9.86 billion.

Sales of the company's top-selling CF drug Trikafta came in at $2.27 billion in the quarter, compared with estimates of $2.26 billion.

Vertex reported third-quarter total sales of $2.48 billion, missing estimates of $2.50 billion.

Last month, a panel of advisers to the U.S. health regulator said Vertex and its partner CRISPR Therapeutics could assess potential safety risks of their gene therapy for sickle cell disease, a type of blood disorder, after approval.

Analysts expect the therapy, a first-of-its-kind product to reach the U.S. Food and Drug Administration for review, to win the health regulator's nod by Dec. 8.

Vertex anticipates the number of CF patients taking the company's medicines will continue to grow, including through new approvals and reimbursement for treatment of younger patients.

On an adjusted basis, the company earned $4.08 per share in the third quarter. Analysts had expected a profit of $3.97.

(Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar and Shounak Dasgupta)

Related Articles

Just like AI, Chinaโ€™s biotech is disrupting the world. Is the US ready? China says rising food demand requires production boost Novartis buys Blackstone's Anthos for up to $3.1 billion Germany's Merck in advanced talks to acquire US biotech firm SpringWorks
Share This

Popular

Business|Political|US|World

Putin envoy on why Americans should believe there will be an outcome in war

Putin envoy on why Americans should believe there will be an outcome in war
Business|Economy|Political|US

Richard Quest explains who feels the immediate impact of Trump tariffs

Richard Quest explains who feels the immediate impact of Trump tariffs
Australia|Business|Finance|Stock Markets

ASX to face investor push back on dual-class listing plans - again

ASX to face investor push back on dual-class listing plans - again
Business|Economy|Finance|Political|US

Oil set for worst week in months over Trump's new tariffs

Oil set for worst week in months over Trump's new tariffs

Health

Crime|Health|US

6 hometown heroes honored for saving man from burning truck

6 hometown heroes honored for saving man from burning truck
Health|Political|US

Federal judge says she will temporarily block billions in health funding cuts to states

Federal judge says she will temporarily block billions in health funding cuts to states
Business|Economy|Finance|Health|Stock Markets

AbbVie cuts 2025 profit forecast on acquisition expenses

AbbVie cuts 2025 profit forecast on acquisition expenses
Economy|Health|Political|US

US Health Dept may ask fired staff to keep working, reinstate others

US Health Dept may ask fired staff to keep working, reinstate others

Access this article for free.

Already have an account? Sign In